Antibody Formulation Stability Using Histidine-Acetate Buffer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Monoclonal antibodies, particularly those binding to HER2 and DR5, face challenges in maintaining stability due to deamidation and aggregation, which are not effectively addressed by existing formulations.
Innovation Solution
A pharmaceutical formulation using a histidine-acetate buffer at pH 5.5 to 6.5, combined with saccharides like trehalose or sucrose and polysorbate 20, to stabilize full-length IgG1 antibodies and prevent deamidation and aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are formulated in conventional buffers, then they can be stored and administered, but they undergo deamidation and aggregation leading to degradation
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range to 5.5-6.5 and selecting specific buffer compositions (histidine-acetate, phosphate, or citrate buffers at controlled concentrations) to minimize deamidation and aggregation. This parameter optimization directly addresses the chemical instability issue by creating a formulation environment that retards degradation pathways while maintaining antibody activity.
Solution Approach 2:
The patent introduces intermediary substances including surfactants (polysorbate 20, polysorbate 80, or TWEEN™ 20 at 0.01-0.1% v/v), sugars (trehalose or sucrose at 1-10% w/v), and amino acids (methionine or histidine at 0.1-5.0 mM) that mediate protection against aggregation and degradation. These intermediaries act as stabilizing agents that prevent direct harmful interactions between antibody molecules and the formulation environment.
2Stability of the object's composition
If monoclonal antibodies are formulated to prevent aggregation, then physical stability improves, but chemical degradation pathways remain active
Solution Approach 1:
The patent employs composite formulation strategies by combining multiple stabilizing components in specific compositions: buffer systems (histidine-acetate, phosphate, or citrate) with controlled pH (5.5-6.5), surfactants (polysorbate 20/80 or TWEEN™ 20), sugars (trehalose/sucrose), and amino acids (methionine/histidine). This composite approach addresses both physical aggregation and chemical degradation simultaneously through synergistic interactions among formulation components.
Solution Approach 2:
The patent applies local quality by optimizing specific formulation parameters at different levels: pH control at 5.5-6.5 range, specific buffer concentrations, controlled surfactant levels (0.01-0.1% v/v), and targeted amino acid additions. Each component is optimized at its local concentration and condition to address specific degradation pathways while maintaining overall formulation compatibility and antibody activity.
Data Source
AI summary
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).